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Abstract
Background: In South Africa, the prevalence of oncogenic Human Papillomavirus (HPV) may be as high as 64%, and cervical
cancer is the leading cause of cancer-related death among women. The development of efficacious prophylactic vaccines
has provided an opportunity for primary prevention. Given the importance of psycho-social forces in vaccine uptake, we
sought to elucidate factors influencing HPV vaccination among a sample of low-income South African adolescents receiving
the vaccine for the first time in Soweto.
Methods: The HPV vaccine was introduced to adolescents in low-income townships throughout South Africa as part of a
nationwide trial to understand adolescent involvement in future vaccine research targeting human immunodeficiency virus
(HIV). We performed in-depth semi-structured interviews with purposively-sampled adolescents and their care providers to
understand what forces shaped HPV vaccine uptake. Interviews were recorded, transcribed, translated, and examined using
thematic analysis.
Results: Of 224 adolescents recruited, 201 initiated the vaccine; 192 (95.5%) received a second immunization; and 164
(81.6%) completed three doses. In our qualitative study of 39 adolescent-caregiver dyads, we found that factors driving
vaccine uptake reflected a socio-cultural backdrop of high HIV endemnicity, sexual violence, poverty, and an abundance of
female-headed households. Adolescents exercised a high level of autonomy and often initiated decision-making. Healthcare
providers and peers provided support and guidance that was absent at home. The impact of the HIV epidemic on decision-
making was substantial, leading participants to mistakenly conflate HPV and HIV.
Conclusions: In a setting of perceived rampant sexual violence and epidemic levels of HIV, adolescents and caregivers
sought to decrease harm by seeking a vaccine targeting a sexually transmitted infection (STI). Despite careful consenting,
there was confusion regarding the vaccine’s target. Future interventions promoting STI vaccines will need to provide
substantial information for participants, particularly adolescents who may exercise a significant level of autonomy in
decision-making.
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Infection with oncogenic Human Papilloma Virus (HPV) is a
necessary precursor for invasive cervical carcinoma (ICC) [1].
HPV and Human Immunodeficiency Virus (HIV) work synergis-
tically to increase the malignant potential of dysplastic cervical
lesions [2,3,4]. South Africa has more HIV-positive citizens than
any country in the world, with nearly 3 million women ages 15
and older currently living with HIV [5], and up to two-thirds have
concomitant oncogenic HPV infections [6,7,8]. HIV-positive
women are nearly five times more likely to have high-risk HPV-
infection compared to HIV-negative women, leading to ICC
becoming the most common cancer-killer among South African
women [9,10,11,12].
Cytology-based screening programs have been the primary tool
for preventing cervical cancer in nations with abundant resources,
however, fewer than 5% of women in low-income nations have
had a single Pap smear, and even fewer have had access to more
advanced interventions such as colposcopy, biopsy, and curettage
[13,14]. Despite the development of efficacious vaccines to prevent
HPV [15,16,17,18], the international movement to expand access
for girls and women living in resource-limited settings has been
slow. Two HPV vaccines are currently available in South Africa
(Gardasil
TM and Cervarix
TM), however, these vaccines have only
remained affordable to the roughly 20–25% of the population who
have had access to private medical insurance [19]. This has left
75–80% of the population who are most at risk for HPV
acquisition, and subsequent morbidity and mortality, unable to
access the vaccine.
The government has recently announced that it will begin to
provide free HPV vaccines to roughly 500,000 low-income nine-
and ten-year-old girls through the public sector in February, 2014
[20]. While increasing distribution of the vaccine remains a focus
in South Africa, research from other settings suggests that simply
ensuring widespread vaccine availability does not always translate
into broad uptake. In nations such as the United States, with
abundant resources, only half of those who initiate the vaccine
ultimately complete the series [21,22]. Research focused on the
multi-dimensional nature of perceived barriers, including vaccine
expense, concerns about adverse effects, discomfort from the
injection, and low perceived need for the vaccine [23], has
provided a framework to understand why vaccine efficacy does not
always translate into vaccine effectiveness, even in settings where
the vaccine is broadly available [24].
A unique challenge of the HPV vaccine is that in order to obtain
maximum effectiveness, the vaccine needs to be administered prior
to an adolescent’s sexual debut [25]. This ultimately requires
understanding decision-making for a young adolescent to receive a
vaccine targeting a sexually transmitted infection (STI). Given the
fact that vaccinating pre-adolescents and adolescents is a relatively
new phenomenon in many resource-limited settings, formative
socio-behavioral research is essential for providing a framework for
optimizing vaccine uptake. Qualitative research in Peru [26],
India [27], Uganda [28], and Vietnam [29,30], illustrate the need
to understand psychosocial barriers to HPV vaccination, including
concerns about vaccine safety and efficacy, and its impact on
future fertility in order to effectively design programs that would
optimize vaccine uptake [31].
In South Africa, prior qualitative research with health care
providers and policy-makers identified concerns regarding how to
promote an STI-vaccine to adolescents and their parents [12].
Additional formative qualitative work has been performed with
South African traditional healers [32], and mothers of adolescents
[33] to assess knowledge, attitudes, and beliefs about HPV and
cervical cancer prevention. These studies have consistently found
that participants had limited knowledge of the link between
cervical cancer and HPV. Despite this, caregivers (who were
primarily identified as mothers) appeared willing to vaccinate their
children. An additional finding from these prior studies that
appears to be unique to the South African context is the concern
raised by participants regarding a child’s risk for rape, and the fact
that access to the HPV vaccine could reduce their risk of HPV
acquisition if they were forced to have unprotected sex.
Community-based participatory research in South Africa has also
highlighted participants’ concerns about the impact of sexual
violence and poverty on reproductive health in general, beyond
cervical cancer prevention [34]. Given the importance of
psychosocial factors in vaccine uptake in nations where it has
been introduced, we sought to elucidate factors influencing HPV
vaccine uptake among a sample of low-income South African
adolescents receiving the vaccine for the first time in the context of
trial modeling uptake of a future HIV vaccine.
Methods
Study Design and Overview
We performed a qualitative study based at Kganya Motsha
Adolescent Centre in Soweto, an urban area of 1.3 million people
in South Africa, with one of the highest rates of HIV transmission
among adolescents worldwide (15–20 year olds are at a 1–2% risk
of acquiring HIV annually) [35]. This clinic, funded through the
United States Agency for International Development (USAID)
and the President’s Emergency Plan for AIDS Relief (PEPFAR)
until 2012, opened in 2008 and has provided adolescents with free
reproductive health services. Kganya Motsha was selected as one
of 6 clinics in low-income townships throughout South Africa to
distribute the HPV vaccine, Gardasil
TM, between April and
September in 2010 to adolescent boys and girls ages 12–19 as part
of an unpublished multi-centre observational cohort study to
model acceptability for a future HIV-vaccine [36]. Those who
accepted the vaccine were offered Gardasil
TM at 0, 2, and 6
months at no-cost. Participants for the parent study were recruited
from neighborhood schools and community outreach and had a
right to refuse the vaccine at any stage of the study. Participants
were simultaneously offered other preventive interventions for
STIs. Participants were required to be HIV-negative, and, for
female participants, not pregnant.
Ethics
All participants provided written informed consent to partici-
pate in the parent study. An institutional review board (IRB)
approved the parent trial protocol at all participating universities,
including the primary site, University of Cape Town. Additional
IRB approval was granted for the qualitative phase of this work at
University of Witwatersrand and Partners Human Research
Committee. Quantitative assessments were performed upon
completion of the informed consent process to verify that all
participants were adequately informed regarding the HPV
vaccine. To enroll in our qualitative study, all adolescents signed
an assent form, and had a caregiver sign an informed consent
release; adolescents less than 18 years old who were without an
adult caregiver were excluded. Consent forms were available in
English, IsiZulu, and Sesotho. All participants were informed that
participation in the study was voluntary and would not prevent
them from receiving the HPV vaccine. South African research
staff trained in qualitative research methods collected interview
data. The caregiver and adolescent were interviewed separately in
private settings to protect confidentiality.
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We recruited adolescents and their caregivers from the parent
trial to participate in an in-depth semi-structured interview. We
used a purposive sampling strategy for this study in order to tap
multiple perspectives on decision-making related to HPV vaccine
acceptability [37]. Trained qualitative researchers individually
interviewed each study participant in their language of choice. The
caregiver and adolescent were interviewed separately and confi-
dentiality was maintained. Inquiry was guided by the domains
from our prior conceptual framework [38]. Topics are shown in
Figure 1. We used an iterative approach throughout the data
collection process [39].
Data Analyses
Interviews were digitally recorded, transcribed, translated as
required, and entered into MAXQDA. Data analysis focused on
characterizing reasons why adolescents and caregivers chose to
initiate the HPV vaccine. Using an inductive approach based
upon grounded theory, categories were constructed to name,
define, and illustrate content themes [40]. We searched interview
data for key concepts that pertained to vaccine-related decision-
making, and displayed the text in matrices to identify patterns.
Patterns of content appearing repeatedly in the data formed the
basis for thematic categories. Once the key concepts were
identified, three researchers developed a codebook (IK, JD and
KP) [41]. This process continued iteratively until intercoder
agreement exceeded 80%, indicating high levels of coder
agreement [42]. Categories could be grouped into broad themes
that provided an integrated explanation of why adolescents and
their caregivers were eager to accept the HPV vaccine. These 4
broad themes are described in the Results section.
Results
Two-hundred and twenty four adolescent participants were
recruited in the parent trial at the Soweto study site, with 201
participants (89.7%) ultimately enrolling. Of these 201 participants
who received the first dose of the vaccine, 192 (95.5%) returned for
a second immunization at the 2-month visit. At the 6 month visit,
164 participants (81.6%) completed the full three doses of the
vaccine. Characteristics of this population from the parent trial are
presented in Table 1. Quantitative assessments were performed at
all sites to assess understanding of the HPV vaccine at the initial
screening after the consent process, prior to receiving the first dose
of the vaccine. Mean scores for the checklist questions (n=212) at
recruitment at the Soweto site were: 11.7/13.
For our qualitative study, we chose a sub-population of
individuals to interview to understand factors driving vaccine
uptake. Forty-eight adults were approached, and ultimately, 39
eligible adolescent-caregiver dyads agreed to participate (n=77).
Over 60% of our 39 adolescent participants were girls and roughly
40% were boys; ranging in age from 12 to 19 years. All adolescents
lived within walking distance to the Kganya Motshe Adolescent
Clinic in the Kliptown section of Soweto. Most participants lived
in informal settlements, which consisted of one to two room
dwellings with tin roofs and cement floors. All 38 caregivers were
women ranging in age between 34 and 61, and all but 2 were
single. While we sought to include perspectives of participants
along a continuum of decision-making, we were only able to
obtain consent from adolescents and their caregivers who chose to
participate in this trial and therefore accept the vaccine. Four
prominent thematic influences on vaccine-related uptake were
inductively identified through data analysis. These themes are
described in detail below:
1) Single-headed Households Leading to Adolescent
Autonomy in Health Decision-making
No male caregivers were identified in our sample. Women often
self-identified as the primary caretakers within the household.
They discussed feelings of hopelessness and an inability to keep
their children safe, particularly as single mothers without a steady
source of income. One mother described her concern that her son
would ‘‘start doing bad things at an early stage,’’ because there was
‘‘no man in this house.’’ The caregivers repeatedly expressed
wanting a ‘‘better life’’ for their children. This ultimately acted as a
strong motivator to get children vaccinated to prevent STIs to
‘‘help our kids to do better.’’ Women also expressed a hope that
Figure 1. Topics of Qualitative Data Collection.
doi:10.1371/journal.pone.0072094.g001
Table 1. Characteristics of Adolescents Presenting for HPV
Vaccination in Soweto.
Sociodemographic Characteristics
Overall N=201
(enrolled)
Age (years) 12–14 141 (70.1%)
15–18+ 60 (29.9%)
Race/Ethnicity Black African 156 (77.6%)
Colored/Other 45(22.4%)
Education level to date Grade 10 13 (6.5%)
Grade 9 26 (12.9%)
Grade 8 36 (17.9%)
,Grade 8 126 (62.7%)
Gender Female Male 129 (64.2%) 72 (35.8%)
doi:10.1371/journal.pone.0072094.t001
Understanding HPV Vaccine Uptake in South Africa
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e72094STI vaccination would prevent their children from becoming
sexually active:
‘‘It is a good thing for our kids because going to the clinic and getting the
vaccine…it helps our kids not to do funny things. Since you can see how
kids are these days. They have sex at an early age and end up being
pregnant and things like that. But now, Kganya Motsha will help us
keep our kids safe, because when my daughter goes for her visit, she will
be checked all the time that she is still a virgin. So, I see it as something
that is going to help me a lot.’’ – 47 year old mother of a 14 year old
girl
Adolescents described their caregivers as overburdened, report-
ing that mothers were often ‘‘stressed’’ and could ‘‘become
cheeky’’ if topics related to sex were raised. Mothers were
described as absent if they were employed. This often translated
into adolescents feeling responsible for ensuring they remain
‘‘safe’’ and avoid early pregnancy or acquire a STI. In this context,
adolescents we interviewed exercised a high level of autonomy in
health decision-making, by going to the clinic alone to find out
about the HPV vaccine trial, and then discussing it with their
caregivers. Caregiver consent was often seen as a formality by the
adolescent. One 14 year old girl mentioned that her mother
agreed she could get the vaccine, but she had ‘‘already decided she
was going to take it.’’ Adolescents often had to educate their
caregivers about the benefits of vaccination, in order to get their
consent to receive the HPV vaccine:
‘‘My mother didn’t want me to go and get the vaccine because she
thought that maybe they will give us AIDS or something. So then I had
to explain to her…and she understood that I wanted to go.’’ – 16 year
old girl
2) Role of Healthcare Providers and Peers in Influencing
Vaccine Uptake and Providing Support
Caregivers expressed difficulty initiating conversations with
their adolescents related to sexual activity or sexual risk-taking,
due to lack of personal information and education. Healthcare
providers at the adolescent clinic were described as adult proxies
who could have conversations with their children about sexual
health, in order to ‘‘provide knowledge about sexual issues.’’
Caregivers described the clinic as a refuge for their children,
providing support and stability that was often unattainable in a
chaotic household:
‘‘My son used to move with a bad group and I thought [enrolling him in
the HPV vaccine trial] would help take him out off the street, so that he
would have something to do after school. It would also help him, so that
when he has questions from school, and I can’t help him, he can go to
the sisters [who work at the clinic] for help.’’ – 33 year old mother of
16 year old boy
Both caregivers and adolescents discussed the importance of
peers in decision-making related to STI prevention. In general,
adults felt that peers provided misinformation to their children,
and encouraged each other to practice risky behavior. While
adolescents acknowledged that peers often had ‘‘naughty behav-
ior’’ that was ‘‘careless,’’ they tended to focus on the positive
impact of peer-influence, particularly in regards to encouraging
vaccine initiation.
‘‘I first went to the clinic. Then my other friend asked me what I was
doing up there. I told him to come and that he would see what everything
was about. He came and they made files for both of us and now we are
both going to get the vaccine.’’ – 13 year old boy
3) STI Vaccination as Harm-reduction Strategy in the
Setting of Endemic Gender Based Violence
Caregivers perceived that adolescents started becoming sexually
active in their early teens. They reported, however, that boys and
girls were likely to become sexually active for different reasons.
Caregivers of girls described sexual violence as being omnipresent,
and adults often felt powerless to protect their children. Adults
often suggested that they were highly motivated to get their
daughters vaccinated against an STI due to a fear of sexual
violence and age-discordant relationships that left girls uniquely
vulnerable. Harm-reduction terminology was used when discuss-
ing the need for young girls to get vaccinated, with mothers often
discussing the inevitability of rape, while hoping their daughters
would be ‘‘protected’’ against acquisition of a STI. In this way,
vaccination was perceived as a way to take control over a situation
where they generally felt powerless:
‘‘I feel certain about [vaccinating my child] because there is AIDS and
HIV out there and we all are aware of it. My child can be raped, and I
will feel bad about it, but I am at peace [knowing] that she is
participating in the Kganya Motsha [HPV vaccine trial] and will be
protected against sexually transmitted diseases.’’– Mother of a 14 year-
old girl
Young people corroborated these views, recognizing that friends
in their age group were sexually active, but that this sexual activity
was often in the form of sexual abuse or was performed in
exchange for money, particularly in the context of an age-
discordant relationship, with older men and younger girls.
Adolescents described friends or neighbors who were raped, and
others who would ‘‘sell themselves just to get money.’’
4) Influence of the HIV Epidemic on Understanding of
HPV Vaccine
All caregivers and adolescents discussed the omnipresence of
HIV in their lives. Adolescents as young as 16 used terminology
such as ‘‘monitoring a CD4 count,’’ and knew the difference
between the HIV virus and an AIDS diagnosis.
‘‘HIV is a virus that causes AIDS. HIV doesn’t kill anybody. It is
AIDS that kills a human being. AIDS is when the CD4 count, the
white blood cells, goes down. So if it happens that the person’s white
blood cells are weak it is easy for other diseases to get him or her and
then that person will die fast.’’ – 16 year old girl
This knowledge often came at the exclusion of knowing about
any other STIs, with adolescents stating they only knew that HIV
and AIDS could be acquired through sexual contact, and did not
know ‘‘any other diseases that come through sex.’’ Despite a basic
understanding of HPV, as demonstrated through the quantitative
testing performed at the beginning of the parent trial, both
adolescents and their caregivers expressed uncertainty in our
interviews about whether the HPV vaccine was also potentially
protective against HIV. Caregivers generally focused on HIV-
prevention, discussing that HIV was ‘‘a death sentence,’’ and that
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PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e72094vaccination against an STI was the only way for their children to
remain safe.
‘‘The thing that really got me interested in this vaccine is because our
youth are dying out with HIV and AIDS, and to me as a parent, I am
very, very, concerned. It is very painful to see the children. They can’t
bury us anymore. We live now to bury them, because of this disease.’’ –
52 year old mother of a 15 year old boy
Discussion
In this qualitative study, we examined adolescents’ and
caregivers’ views of HPV vaccination in order to understand
factors influencing vaccine uptake in Soweto, South Africa. We
found that factors driving vaccine uptake reflected a socio-cultural
backdrop of high HIV endemnicity, sexual violence, poverty, and
an abundance of female-headed households. Within this context,
adolescents exercised a high level of autonomy, and often initiated
decision-making. These qualitative findings build on prior research
performed in South Africa related to HPV vaccine acceptability
[33,43,44], and provide a context for understanding how
adolescents and caregivers view the HPV vaccine, establishing a
framework for optimizing programs that would introduce the
HPV vaccine into the public health sector in South Africa [19].
While prior studies have focused on caregivers being the
primary decision-makers regarding youth vaccination [45,46], we
found that most decisions made relating to HPV vaccine uptake
were youth-driven. Prior research in South Africa has described
the ‘‘feminization of poverty’’ as a situation in which young poor
women, acting as the head of the household, are at unique risk
[47]. Our data show that in this setting, adolescents are highly self-
reliant and exercise great autonomy in decision-making, ultimately
leading them to play a significant role in choosing whether or not
to accept an STI vaccine. These findings shed light on the
importance of understanding developmental factors within this
larger social context of adolescent-autonomy, and the need to
develop programs involving healthcare providers to engage young
people in effective decision-making strategies.
This study also provided a unique perspective among adolescent
participants, specifically the involvement of boys. While most
qualitative research in resource-limited settings related to HPV
vaccine uptake has focused on girls, prior findings in resource-rich
settings have been performed with boys and men. Results from
those studies show that boys may mistakenly posit that HPV only
affects girls [48]. Despite this, boys have been shown to be
important partners in decision-making [49], and quantitative
studies have confirmed that boys are amenable to receiving the
HPV vaccine [50], particularly if it is offered in conjunction with
other recommended adolescent vaccines [51]. Our research
furthers these findings by demonstrating that boys can be partners
in decision-making (even, at times, taking the lead), and that it is
feasible to administer a vaccine to an adolescent, even in the
absence of an infrastructure to vaccinate young adults.
Our finding related to the fear of gender-based violence and age
discordant relationships has been seen as a driver of vaccine
uptake previously in South Africa [32,33,52,53]. South Africa is
reported to have one of the highest rates of sexual assault in the
world, with girls between the ages of 12–15 at highest risk
[54,55,56,57,58]. Fear of becoming a victim of sexual violence is
commonly held in South Africa. In the most recent ‘‘Victims of
Crime’’ survey, published by the South African Government [59],
nearly a third (27.1%) of households feared sexual violence
(including rape) more than other crimes in their area. While
caregivers expressed deep concern about the level of sexual
violence in their community, our data support the use of a ‘‘harm
reduction’’ strategy as a way to protect young girls from STI
acquisition while recognizing the reality of gender-based violence
in Soweto.
Finally, when considering the term ‘‘vaccine acceptability,’’ we
need to recognize that participants expressed a limited under-
standing of the HPV vaccine, despite careful counseling. While
these findings mirror prior results in South Africa [33,44], our
study adds a unique perspective by specifically providing evidence
of real-time HPV vaccine uptake despite this misconception.
Confusion regarding HPV and HIV may reflect the fact that this
trial used the HPV vaccine as a proxy for future HIV vaccination
among adolescents, as well as the larger context of post-apartheid
South Africa, where HIV has remained at epidemic levels [60].
Knowledge of HPV and its associated diseases has been found to
be low [33], despite cervical cancer being the leading cancer-
associated cause of death among South African women [12,44].
Despite this, we believe that our findings show that this population
of adolescents and their caregivers are highly motivated to seek
interventions to help prevent the transmission of STIs. These
interventions carry some degree of burden (specifically returning
for a vaccine three times over the course of six months). This is
novel, especially given the lack of adolescent vaccination programs
in place in South Africa at this time.
This study had the notable limitation of being performed in the
context of an observational trial. Participants who are part of a
trial may be more likely to trust clinicians, which itself may be
correlated with vaccine uptake. This phenomenon has been
considered in other HPV trials [61]. In addition, the HPV vaccine
was provided at no-cost for participants in this study, thereby
enriching our sample of HPV vaccine accepters for adolescents
and caregivers from low-income households. In addition, our
study is exploratory in nature, and focused on identifying thematic
influences on vaccine uptake and understanding relationships
between these concepts without assigning a relative importance to
these themes. Therefore, our findings cannot be generalizable to a
larger population of adolescents and their caregivers. Rather, these
findings provide an in-depth understanding of a specific context
occurring in Soweto. Finally, given that fears of sexual violence,
and experience of sexual violence itself, are associated with poverty
[62,63], our findings may have over-emphasized its relative
importance in decision-making. Despite these limitations, these
findings support prior research done at this site in Soweto where
adolescents and their caregivers were eager to participate in
biomedical prevention trials, and supports the translation of this
willingness to participate to actual health-seeking behavior [64].
Conclusions
Our findings provide an initial framework to understand STI
vaccine uptake in a setting such as Soweto with epidemic levels of
HIV, sexual violence, poverty, and an abundance of female-
headed households. Future interventions should specifically target
adolescents in female-headed households to assess acceptability
and feasibility of STI primary-prevention strategies, while
providing extensive education to adolescents and their caregivers
about HPV, as well as other modalities of cervical cancer
prevention.
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